Achieve Life Sciences announced the results from a series of studies on drug metabolism, drug-drug interaction, and transporter studies with cytisine.
The results showed that cytisine can be administered with other medications that the patient might be taking without any changes in the drug dosage. Cytisine was found to have “no clinically significant interaction with any of the hepatic enzymes commonly responsible for drug metabolism nor clinically significant interaction with drug transporters.”
Dr. Anthony Clarke, Achieve Life Sciences’ chief scientific officer, said, “We are very pleased with the results of these detailed studies. Smokers are as likely as anyone to take medications for a range of conditions. These results suggest that cytisine is unlikely to interfere with their ability to take other medications safely, and should help to minimize restrictions on the eligibility of subjects in our forthcoming clinical trials expected to commence later this year.”
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!
Source: https://marketrealist.com/2018/06/achieve-life-sciences-stock-rose-positive-data-on-cytisine/